Table 1 Baseline Characteristics in Unmatched and Propensity-Matched Cohorts of Patients Hospitalized with COVID-19.
Unmatched | Matched | |||||
|---|---|---|---|---|---|---|
Total N = 2626 | Statin use 951 (36.2%) | No statin use 1675 (63.8%) | p value | Statin use (n = 648) | No statin use (n = 648) | p value |
Demographics | ||||||
Age, years, median (IQR) | 70 (63–79) | 62 (49–76) | <0.001 | 69 (61–77) | 71 (60–81) | 0.18 |
Body mass index (kg/m2) | 28.3 (24.7–32.8) | 27.9 (24.5–32.6) | 0.23 | 28.1 (24.7–32.4) | 27.1 (23.8–32.0) | 0.66 |
Sex | 0.06 | 1.0 | ||||
Male | 519 (34.7%) | 978 (65.3%) | 366 (56.5%) | 366 (56.5%) | ||
Female | 432 (38.2%) | 697 (61.7%) | 282 (43.5%) | 282 (43.5%) | ||
Race/Ethnicity | 0.12 | 0.76 | ||||
Hispanic | 489 (51.4%) | 825 (49.2%) | 327 (50.5) | 310 (47.8%) | ||
Non-Hispanic White | 88 (9.3%) | 149 (8.9%) | 60 (9.3%) | 68 (10.5%) | ||
Non-Hispanic Black | 126 (13.2%) | 194 (11.6%) | 87 (13.4%) | 87 (13.4%) | ||
Others/Missing | 248 (26.1%) | 507 (30.3%) | 174 (26.9%) | 183 (28.2%) | ||
Location | 0.88 | 0.50 | ||||
Manhattan | 553 (58.1%) | 936 (55.9%) | 371 (57.3%) | 381 (58.8%) | ||
Brooklyn | 24 (2.5%) | 46 (2.7%) | 16 (2.5%) | 12 (1.9%) | ||
Queens | 29 (3.0%) | 47 (2.8%) | 25 (3.9%) | 16 (2.5%) | ||
Bronx | 294 (3.1%) | 546 (3.3%) | 197 (30.4%) | 209 (32.2%) | ||
Staten Island | 2 (0.2%) | 4 (0.2%) | 2 (0.3%) | 1 (0.1%) | ||
Outside NYC | 49 (5.1%) | 96 (5.7%) | 37 (5.7%) | 29 (4.5%) | ||
Insurance | <0.001 | 0.80 | ||||
Medicare/Medicaid | 599 (63.0%) | 896 (53.6%) | 396 (61.1%) | 399 (61.6%) | ||
Commercial | 337 (35.4%) | 710 (42.5%) | 241 (37.2%) | 235 (36.2%) | ||
Other/Uninsured | 15 (1.6%) | 65 (3.9%) | 11 (1.7%) | 14 (2.1%) | ||
Comorbidities | ||||||
Hypertension | 704 (74.0%) | 726 (43.3%) | <0.001 | 434 (67.0%) | 453 (69.9%) | 0.28 |
Diabetes | 531 (55.8%) | 437 (26.1%) | <0.001 | 297 (45.8%) | 309 (47.7%) | 0.54 |
Coronary artery disease | 214 (22.5%) | 115 (6.9%) | <0.001 | 96 (14.8%) | 91 (14.0%) | 0.75 |
Heart failure | 162 (17.0%) | 113 (6.7%) | <0.001 | 91 (14.0%) | 78 (12.0%) | 0.32 |
Chronic lung disease | 196 (20.6%) | 267 (15.9%) | <0.01 | 124 (19.1%) | 124 (19.1%) | 1.0 |
Chronic kidney disease | 209 (22.0%) | 161 (9.6%) | <0.001 | 116 (17.9%) | 113 (17.4%) | 0.88 |
Stroke/TIA | 132 (13.9%) | 93 (5.6%) | <0.001 | 68 (10.5%) | 67 (10.3%) | 1.0 |
Atrial arrhythmiasa | 105 (11.0%) | 118 (7.0%) | <0.001 | 64 (9.9%) | 61 (9.4%) | 0.85 |
Liver disease | 31 (3.3%) | 53 (3.2%) | 0.98 | 22 (3.4%) | 21 (3.2%) | 1.0 |
Home medications | ||||||
ACE inhibitors | 187 (19.7%) | 70 (4.2%) | <0.001 | 76 (11.7%) | 63 (9.7%) | 0.28 |
ARBs | 125 (13.1%) | 62 (3.7%) | <0.001 | 60 (9.3%) | 52 (8.0%) | 0.49 |
P2Y12 inhibitors | 113 (11.9%) | 20 (1.1%) | <0.001 | 35 (5.4%) | 20 (3.1%) | 0.05 |
Oral anticoagulants | 193 (20.3%) | 206 (12.3%) | <0.001 | 111 (17.1%) | 118 (18.2%) | 0.66 |
Beta-blockers | 419 (44.0%) | 212 (12.7%) | <0.001 | 194 (29.9%) | 177 (27.3%) | 0.32 |
Inpatient statins | 732 (77.0%) | 144 (8.6%) | <0.001 | 487 (75.1%) | 86 (13.3%) | <0.001 |
Lipid profile (n = 850) | ||||||
Total cholesterol | 157.3 (127.7–191.0) | 164.9 (136.0–201.9) | <0.01 | |||
Low-density lipoprotein | 77.9 (60.0–107.6) | 88.0 (67.0–117.0) | <0.01 | |||
High-density lipoprotein | 43.0 (34.0–54.4) | 42.0 (32.4–54.4) | 0.25 | |||
Triglycerides | 136.0 (98.0–187.8) | 136.0 (93.7–215.5) | 0.22 | |||
